lencana Anda Rentang 52M $83–$133 60% of range Peringkat Analis HOLD 35 analysts Target Harga $129 +14% upside P/E 14.4 ROE 30.7% Margin Laba Bersih 27.7%

INCY Cuplikan Saham Harga, kapitalisasi pasar, P/E, EPS, ROE, utang/ekuitas, kisaran 52 minggu

03
Harga $112.73
Kapitalisasi Pasar (MRQ) $22.66B
P/E (TTM) 14.4
EPS (TTM) $7.85
Pendapatan (TTM) $5.82B
ROE (TTM) 30.7%
Rentang 52M $83–$133

INCY Grafik Harga Saham OHLCV harian dengan indikator teknis — geser, perbesar, dan sesuaikan tampilan Anda

04
rentang
batang

Granularitas batang menyesuaikan dengan periode yang dipilih — arahkan kursor ke bagan untuk melihat buka/tinggi/rendah/tutup untuk sebuah batang.

Pemecahan saham 2
Tanggal ex-dividen Pemecahan Tipe
1 Sep. 2000 2-for-1 Maju
10 Nov. 1997 2-for-1 Maju

Tentang Incyte Corporation - Common Stock Tinjauan perusahaan dari Wikipedia

05 · wikidata

Incyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware. The company currently operates manufacturing and R&D locations in North America, Europe, and Asia.

Incyte Corporation currently develops and manufactures prescription biopharmaceutical medications in multiple therapeutic areas including oncology, inflammation, and autoimmunity.

History

Incyte Corporation was founded by Roy A. Whitfield on April 8, 1991, in Palo Alto, California, as a genomics company. It became a public company in 1993. Subsequently, scientists and chemists were recruited from DuPont to work for Incyte. Incyte moved its headquarters to Delaware, and acquired Maxia Pharmaceuticals in 2003.

In November 2013, Incyte announced its relocation to new headquarters in Wilmington, Delaware, completing the move by the end of 2014. Hervé Hoppenot became CEO in January 2014.

In 2017, the company became part of the S&P 500 Index, which tracks the 500 most widely held U.S. stocks.

In 2015, Incyte established its European headquarters in Geneva, Switzerland, and later moved this headquarters in 2021. The company expanded its Delaware headquarters, including the addition of a research and development facility, in 2022. Incyte acquired Villaris Therapeutics in 2022, and Escient Pharmaceuticals in 2024.

For 2025, the company reported $5.141 billion in revenue, $6.957 billion in assets and $1.286 billion in net income. Incyte is publicly traded on the NASDAQ under the symbol INCY. Incyte now operates out of North America, Asia, and Europe. Bill Meury became CEO in 2025. Meury replaced Hoppenot, who retired after 11 years in the position.

Pharmaceuticals

Incyte Corporation currently has seven marketed and co-marketed pharmaceutical products, including Jakafi (ruxolitinib), Pemazyre (pemigatinib), Monjuvi (tafasitamab-cxix), Opzelura (Ruxolitinib), Tabrecta (capmatinib), Olumiant (Baricitinib), and Iclusig (ponatinib).

In 2013, Novartis acquired Incyte's c-Met inhibitor capmatinib (INC280, INCB028060), which is marketed under the brand name Tabrecta.

As of 2014, the company was developing baricitinib, an oral JAK1 and JAK2 inhibitor drug for rheumatoid arthritis in partnership with Eli Lilly. It gained EU approval in February 2017. In April 2017, the US FDA issued a rejection, citing concerns about dosing and safety. In May 2018, baricitinib was approved in the United States for the treatment of rheumatoid arthritis under the brand name Olumiant.

As of 2016 epacadostat, an indoleamine 2,3-dioxygenase (IDO1) inhibitor, was in development for various cancers and was in combination trials with Merck's pembrolizumab (Keytruda) and Bristol Myers Squibb's nivolumab (Opdivo).

Acquisition history

Incyte has made a total of 3 acquisitions.

Maxia Pharmaceuticals (2003): An early acquisition in Incyte's history, the company purchased Maxia in 2003 for $42 million.

Villaris Therapeutics (2022): This acquisition was valued at approximately $1.4 billion and included an upfront payment along with milestones. It added new assets to Incyte's portfolio for treating vitiligo and other autoimmune conditions.

Escient Pharmaceuticals (2024): In May 2024, Incyte acquired this San Diego-based, clinical-stage company for $750 million. The acquisition provided Incyte with two oral drug candidates for inflammatory diseases, EP262 and EP547.

Sumber: Wikipedia (English), CC BY-SA 4.0 · Lihat di Wikipedia ↗

Wikidata ↗

sektorHealthcare industriBiotechnology karyawan2.844 negaraUS

Kinerja 10 Tahun Tren Pendapatan, laba bersih, margin, dan EPS

06
Pendapatan$5.14B
2016-12-31 → 2025-12-31
EPS$6.41
2016-12-31 → 2025-12-31
Arus Kas Bebas·
2017-12-31 → 2022-12-31
Margin bersih27.7%
2018-12-31 → 2025-12-31
Valuasi & Rasio 07–12

Valuasi Rasio P/E, P/S, P/B, EV/EBITDA — apakah sahamnya mahal atau murah?

Metrik Tren 5 Tahun INCY rata-rata 5T Median Rekan Kesimpulan
P/E (TTM) 14.4rata-rata 5T ≈113.9 ≈113.9 22.0 Kurang nilai
P/S (TTM) 3.9rata-rata 5T ≈4.4 ≈4.4 7.3 Kurang nilai
P/B (MRQ) 3.6rata-rata 5T ≈4.0 ≈4.0 6.1 Kurang nilai
Price / Cash Flow (Harga / Arus Kas) 15.8rata-rata 5T ≈23.5 ≈23.5 13.9 Nilai wajar
Price / Tangible Book (Harga / Nilai Buku Berwujud) 4.4rata-rata 5T ≈3.9 ≈3.9 · ·

Median rekan dihitung berdasarkan basis standar per metrik dan mungkin tidak selalu cocok dengan basis TTM/MRQ yang ditampilkan untuk saham ini.

nilai · ≈ rata-rata 5T · median industri · penilaian relatif terhadap median

Riwayat Pendapatan EPS aktual vs perkiraan, kejutan %, tingkat keberhasilan, tanggal pendapatan berikutnya

14
Kejutan Rata-rata 19.2%
Laporan Berikutnya Okt 26, 2026
PeriodeLaporanEPS AktualEPS EstimasiKejutan
30 Juni 2026 Jul 27, 2026 $3.09 $2.14 44.1%
31 Maret 2026 $1.81 $1.40 29.4%
31 Des. 2025 $1.80 $1.97 -8.5%
30 Sep. 2025 $2.26 $1.69 33.7%
30 Juni 2025 $1.57 $1.50 4.7%
31 Maret 2025 $1.16 $1.04 11.9%

Fundamental Lengkap Semua metrik per tahun — laporan laba rugi, neraca, arus kas

15
Laporan Laba Rugi 17
Metrik Tren 202520242023202220212020201920182017201620152014
Revenue $5.14B$4.24B$3.70B$3.39B$2.99B$2.67B$2.16B$1.88B$1.54B$1.11B$754M$511M
Cost of Revenue $372M$312M$255M$207M$151M$131M$114M$94M$79M$58M$27M$3M
R&D Expense $2.05B$2.61B$1.63B$1.59B$1.46B$2.22B$1.15B$1.20B$1.33B$582M$480M$348M
SG&A Expense $1.38B$1.24B$1.16B$1.00B$740M$517M$469M$434M$366M$303M$197M$166M
Operating Expenses $3.63B$4.18B$3.08B$2.82B$2.40B$2.93B$1.76B$1.75B$1.78B$961M$703M$516M
Operating Income $1.51B$61M$621M$579M$586M$-264M$402M$129M$-243M$145M$51M$-5M
Interest Expense ··$3M$3M$2M$2M$2M$2M$7M$39M$46M$47M
Interest Income $106M$129M$158M$40M········
Other Non-op $25M$13M$14M$-519.0K$11M$23M$52M$32M$17M···
Pretax Income $1.66B$317M$834M$529M$570M$-232M$487M$115M$-312M$107M$8M$-49M
Income Tax $378M$284M$237M$188M$-378M$63M$40M$6M$852.0K$3M$1M$-66.0K
Net Income $1.29B$33M$598M$341M$949M$-296M$447M$109M$-313M$104M··
EPS (Basic) $6.59$0.16$2.67$1.53$4.30$-1.36$2.08$0.52$-1.53$0.55$0.04$-0.29
EPS (Diluted) $6.41$0.15$2.65$1.52$4.27$-1.36$2.05$0.51$-1.53$0.54$0.03$-0.29
Shares (Basic) 195,204,000207,110,000223,628,000222,004,000220,428,000218,073,000214,913,000212,383,000204,580,000187,873,000179,601,000167,947,000
Shares (Diluted) 200,700,000210,530,000225,928,000223,958,000222,074,000218,073,000217,657,000215,635,000204,580,000194,125,000187,302,000167,947,000
EBITDA $1.61B$151M·$647M$644M$-212M$457M$184M$-192M··$37M
Neraca 27
Metrik Tren 202520242023202220212020201920182017201620152014
Cash & Equivalents $3.10B$1.69B$3.21B$2.95B$2.06B$1.51B$1.83B$1.16B$900M$652M$521M$452M
Short-term Investments ······$285M$274M$270M$156M$186M$148M
Inventory $101M$59M$63M$42M$28M$16M$11M$7M$6M$4M$2M$358.0K
Prepaid Expense $318M$169M$183M$167M$126M$60M$44M$79M$62M$33M$18M$21M
Current Assets $5.02B$3.24B$4.65B$4.09B$3.12B$2.36B$2.48B$1.83B$1.50B$994M$842M$680M
PP&E (Net) $731M$763M$752M$739M$724M$560M$378M$320M$260M$168M$86M$82M
PP&E (Gross) $1.11B$1.09B$1.02B$952M$900M$704M$499M$423M$334M$219M$131M$116M
Accum. Depreciation $375M$328M$270M$213M$176M$144M$122M$103M$75M$52M$45M$35M
Goodwill $133M$156M$156M$156M$156M$156M$156M$156M$156M$156M··
Intangibles ········$237M$270M$12M$2M
Other Non-current Assets $18M$11M$52M$25M$37M$39M$49M$19M$2M$3M$12M·
Total Assets $6.96B$5.44B$6.78B$5.84B$4.93B$3.56B$3.43B$2.65B$2.30B$1.64B$1.01B$796M
Accounts Payable $210M$197M$110M$278M$172M$99M$84M$104M$68M$76M$30M$24M
Accrued Liabilities $1.03B$1.21B$936M$701M$534M$378M$286M$229M$199M$127M$87M$62M
Current Liabilities $1.52B$1.64B$1.24B$1.16B$854M$631M$513M$425M$375M$274M$168M$221M
Capital Leases $15M$17M$14M$14M$16M$14M$12M·····
Deferred Tax ···········$20M
Other Non-current Liabilities $165M$168M$149M$99M$70M$58M$40M$22M$20M$13M$48M$55M
Total Liabilities $1.79B$2.00B$1.59B$1.47B$1.16B$950M$828M$720M$672M$1.22B$836M$878M
Long-term Debt ·······$19.09B$27M$750M$750M$841M
Total Debt ···········$689M
Common Stock $198.0K$193.0K$224.0K$223.0K$221.0K$219.0K$216.0K$213.0K$211.0K$189.0K$187.0K$171.0K
Retained Earnings $214M$-1.07B$160M$-437M$-778M$-1.73B$-1.43B$-1.88B$-1.99B$-1.67B$-1.78B$-1.79B
AOCI $25M$-13M$13M$15M$-19M$-15M$-16M$-10M$-7M$-3M$-809.0K$2M
Stockholders' Equity $5.17B$3.45B$5.19B$4.37B$3.77B$2.61B$2.60B$1.93B$1.63B$419M$171M$-82M
Liabilities + Equity $6.96B$5.44B$6.78B$5.84B$4.93B$3.56B$3.43B$2.65B$2.30B$1.64B$1.01B$796M
Shares Outstanding 198,460,009193,434,305224,286,862222,746,719221,084,433219,489,329216,177,830213,274,660211,262,906188,848,752186,650,249170,876,619
Arus Kas 16
Metrik Tren 202520242023202220212020201920182017201620152014
D&A $93M$89M$83M$68M$58M$52M$55M$55M$52M$58M$45M$41M
Stock-based Comp $249M$266M$216M$188M$183M$178M$167M$148M$133M$96M$70M$62M
Deferred Tax $248M$-86M$-159M$57M$-466M$-350.0K$-377.0K$-459.0K$-805.0K···
Amort. of Intangibles $27M$24M$22M$22M$22M$22M$22M$22M$22M$13M··
Other Non-cash $-463M$33M·$316M$26M$-58M$43M$24M····
Operating Cash Flow $1.41B$335M$496M$970M$749M$-125M$711M$336M$-93M$305M$89M$26M
CapEx ···$78M$181M$187M$78M$73M$111M$120M$26M$28M
Investing Cash Flow $-103M$158M$-208M$-79M$-208M$-269M$-87M$-86M$-350M$-232M$-105M·
Stock Issued ········$649M···
Stock Repurchased $0$2.00B$0$0········
Net Stock Activity $0$-2.00B······$649M···
Financing Cash Flow $101M$-2.02B$-20M$-794.0K$6M$72M$46M$15M$690M$45M$85M·
Net Change in Cash $1.41B$-1.53B$262M$894M$544M$-319M$669M$265M$247M$117M$69M$-19M
Taxes Paid $212M$373M$378M$136M$68M$71M$34M$5M$6M$927.0K··
Free Cash Flow ···$892M$568M$-312M$633M$263M$-204M··$-2M
Levered FCF ···$890M$565M$-315M$631M$261M$-211M··$-48M
Profitabilitas 7
Metrik Tren 202520242023202220212020201920182017201620152014
Operating Margin 29.5%1.5%·17.1%19.6%-9.9%18.6%6.9%-15.9%··-0.94%
Net Margin 25.0%0.77%·10.0%31.8%-11.1%20.7%5.8%····
Pretax Margin 32.4%7.5%·15.6%19.1%-8.7%22.6%6.1%-20.3%··-9.5%
EBITDA Margin 31.3%3.5%·19.1%21.6%-7.9%21.1%9.8%-12.5%··7.2%
ROA 20.8%0.53%·6.3%22.3%-8.5%14.7%4.4%····
ROE 27.6%0.99%·7.9%27.4%-11.8%17.8%5.9%····
ROIC 22.7%0.18%·8.5%25.8%-12.9%14.2%6.4%-15.0%··-0.79%
Likuiditas & Solvabilitas 4
Metrik Tren 202520242023202220212020201920182017201620152014
Current Ratio 3.32.0·3.53.73.74.84.34.0··3.2
Quick Ratio 2.01.0·2.62.42.44.13.43.1··2.7
Debt / Equity ···········-8.4
Interest Coverage ···217.3307.0-121.3216.783.7-35.3··-0.1
Efisiensi 2
Metrik Tren 202520242023202220212020201920182017201620152014
Asset Turnover 0.80.7·0.60.70.80.70.80.8··0.7
Inventory Turnover 4.75.1·5.96.89.412.414.015.0··7.9
Per Saham 5
Metrik Tren 202520242023202220212020201920182017201620152014
Book Value / Share $26.04$17.82·$19.62$17.05$11.90$12.02$9.03$7.72···
Revenue / Share $25.62$20.15·$15.16$13.45$12.23$9.92$8.73$7.51···
Cash Flow / Share $7.04$1.59·$4.33$3.37$-0.57$3.27$1.56$-0.45···
Cash / Share $15.61$8.73·$13.25$9.31$6.89$8.48$5.46$4.26···
EPS (TTM) $6.41$0.15$2.65$1.52$4.27$-1.36$2.05$0.51$-1.53$0.54$0.03$-0.29
Tingkat Pertumbuhan 7
Metrik Tren 202520242023202220212020201920182017201620152014
Revenue YoY 21.2%14.8%8.9%13.7%12.0%·······
Revenue CAGR 3Y 14.8%12.4%11.5%·········
Revenue CAGR 5Y 14.0%···········
EPS YoY 4173.3%-94.3%74.3%-64.4%········
EPS CAGR 3Y 61.6%-67.2%··········
Net Income YoY 3845.0%-94.5%75.4%-64.1%········
Net Income CAGR 3Y 55.7%-67.5%··········
Valuasi (TTM) 10
Metrik Tren 202520242023202220212020201920182017201620152014
Revenue TTM $5.14B$4.24B$3.70B$3.39B$2.99B$2.67B$2.16B$1.88B$1.54B$1.11B$754M$511M
Net Income TTM $1.29B$33M$598M$341M$949M$-296M$447M$109M$-313M$104M··
Market Cap $19.60B$13.36B·$17.89B$16.23B$19.09B$18.88B$13.56B$20.01B···
P/E 15.4460.523.752.817.2-64.042.6124.7-61.9185.73615.0-252.1
P/S 3.83.2·5.35.47.28.77.213.0···
P/B 3.83.9·4.14.37.37.37.012.3···
P / Tangible Book 3.94.12.84.24.57.8······
P / Cash Flow 13.939.8·18.421.7-153.226.640.3-215.2···
P / FCF ···20.128.5-61.229.851.6-98.1···
Earnings Yield 6.5%0.22%4.2%1.9%5.8%-1.6%2.4%0.80%-1.6%0.54%0.03%-0.40%

Periode terbaru di sebelah kiri · nilai null ditampilkan sebagai ·

Laporan Keuangan Laporan laba rugi, neraca, arus kas — tahunan, 5 tahun terakhir

16
Metrik 2025-12-312024-12-312023-12-312022-12-312021-12-31
Pendapatan $5.14B $4.24B $3.70B $3.39B $2.99B
Margin Operasi % 29.5% 1.5% · 17.1% 19.6%
Laba Bersih $1.29B $33M $598M $341M $949M
EPS Dilusian $6.41 $0.15 $2.65 $1.52 $4.27

Pemilik institusional (13F) 919 pengaju · $24.0B total · Per tanggal 30 Sep. 2026

17

Institusi yang melaporkan kepemilikan saham ini dalam SEC Form 13F triwulanan mereka. Hanya posisi panjang; satu pengaju dapat muncul dua kali untuk leg opsi terpisah. Kaki put/call offset yang besar biasanya mencerminkan pembuatan pasar atau inventaris yang dilindungi, bukan keyakinan arah.

Pemegang 919
Nilai yang dipegang $24.0B
Posisi baru 123
Posisi yang keluar 68
Aktivitas institusional — Q2 2026 vs kuartal sebelumnya
Posisi baru Posisi yang keluar Meningkat Menurun Perubahan bersih saham
123 (-4 vs Kuartal sebelumnya) 68 (-29 vs Kuartal sebelumnya) 356 (+47 vs Kuartal sebelumnya) 274 (-17 vs Kuartal sebelumnya) +1.4M

Dibandingkan dengan Q1 2026. Pengajuan Formulir 13F SEC jatuh tempo dalam waktu 45 hari setelah akhir kuartal ditambah kelonggaran singkat untuk pengaju terlambat — kuartal yang masih dalam jangka waktu tersebut dilewati demi pasangan terakhir yang dilaporkan sepenuhnya.

Institusi Nilai Saham % dari 13F yang dilacak Tipe
BAKER BROS. ADVISORS LP $3.487.217.729 30.762.330 14,52% Saham
BlackRock, Inc. $2.044.188.907 18.032.718 8,51% Saham
VANGUARD GROUP INC $1.966.652.336 19.911.434 8,19% Saham
Dodge & Cox $1.355.482.475 11.957.326 5,64% Saham
VANGUARD CAPITAL MANAGEMENT LLC $1.249.713.401 11.024.289 5,20% Saham
STATE STREET CORP $1.102.124.009 9.722.336 4,59% Saham
VANGUARD PORTFOLIO MANAGEMENT LLC $883.198.076 7.791.091 3,68% Saham
AQR CAPITAL MANAGEMENT LLC $603.177.347 5.320.901 2,51% Saham
GEODE CAPITAL MANAGEMENT, LLC $536.515.860 4.750.735 2,23% Saham
Invesco Ltd. $462.561.060 4.080.461 1,93% Saham
WELLINGTON MANAGEMENT GROUP LLP $405.321.059 3.575.521 1,69% Saham
RENAISSANCE TECHNOLOGIES LLC $398.135.284 3.512.132 1,66% Saham
MORGAN STANLEY $334.226.735 2.948.364 1,39% Saham
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP $311.168.439 2.744.958 1,30% Saham
Robeco Institutional Asset Management B.V. $276.795.075 2.441.735 1,15% Saham
GOLDMAN SACHS GROUP INC $261.383.430 2.305.782 1,09% Saham
DIMENSIONAL FUND ADVISORS LP $258.591.850 2.280.803 1,08% Saham
TWO SIGMA INVESTMENTS, LP $227.123.448 2.003.559 0,95% Saham
NORTHERN TRUST CORP $199.736.467 1.761.966 0,83% Saham
CHARLES SCHWAB INVESTMENT MANAGEMENT INC $191.854.885 1.692.439 0,80% Saham
Legal & General Group Plc $182.053.894 1.605.980 0,76% Saham
FIRST TRUST ADVISORS LP $180.015.041 1.587.996 0,75% Saham
VICTORY CAPITAL MANAGEMENT INC $167.811.569 1.480.342 0,70% Saham
FMR LLC $156.637.793 1.381.773 0,65% Saham
Caisse de depot et placement du Quebec $155.360.220 1.370.503 0,65% Saham
MARSHALL WACE, LLP $148.519.056 1.310.154 0,62% Saham
HSBC HOLDINGS PLC $148.336.065 1.307.743 0,62% Saham
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC $145.030.732 1.540.913 0,60% Saham
DEUTSCHE BANK AG\ $143.172.320 1.262.988 0,60% Saham
AustralianSuper Pty Ltd $135.634.220 1.196.491 0,56% Saham
Amundi $133.934.668 1.181.498 0,56% Saham
ROYAL BANK OF CANADA $128.327.000 1.132.050 0,53% Saham
NORGES BANK $126.861.970 1.119.107 0,53% Saham
Bank of New York Mellon Corp $110.279.448 972.825 0,46% Saham
Man Group plc $108.025.392 952.941 0,45% Saham
VANGUARD FIDUCIARY TRUST CO $106.959.694 943.540 0,45% Saham
BNP PARIBAS ASSET MANAGEMENT Holding S.A. $106.304.813 937.763 0,44% Saham
ARMISTICE CAPITAL, LLC $102.024.567 900.005 0,42% Saham
PANAGORA ASSET MANAGEMENT INC $99.970.937 881.889 0,42% Saham
JPMORGAN CHASE & CO $87.335.467 761.690 0,36% Saham
UBS Group AG $87.051.865 767.924 0,36% Saham
Sound Shore Management Inc /CT/ $85.895.479 757.723 0,36% Saham
JACOBS LEVY EQUITY MANAGEMENT, INC $82.953.901 731.774 0,35% Saham
Gotham Asset Management, LLC $81.567.621 719.545 0,34% Saham
Pictet Asset Management Holding SA $81.315.880 713.354 0,34% Saham
BANK OF AMERICA CORP /DE/ $76.653.013 676.191 0,32% Saham
MACKENZIE FINANCIAL CORP $71.967.956 634.862 0,30% Saham
CITIGROUP INC $66.477.819 586.431 0,28% Saham
LOS ANGELES CAPITAL MANAGEMENT LLC $65.633.852 578.986 0,27% Saham
FRANKLIN RESOURCES INC $63.330.037 558.663 0,26% Saham

Tampilkan semua 919 pemilik institusional →

Aktivis & pemilik 5%+ 7 saham

18

Investor yang mengajukan Jadwal 13D SEC — kepemilikan manfaat di atas 5% dengan niat untuk memengaruhi penerbit (kepemilikan aktivis, kampanye dewan, M&A). Setiap baris menunjukkan status terbaru yang diketahui dari posisi pengaju tersebut.

Pengaju Diajukan Kepemilikan Status Tujuan Pengajuan
Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Julian C. Baker, Felix J. Baker, FBB2, LLC, FBB3 LLC, FBB Associates ×21 pengajuan 11 Mei 2026 15,60% Amandemen Investasi pasif SEC
Incyte Corporation ×3 pengajuan 14 Agu 2023 · Pengajuan awal Struktur modal SEC
Baker Bros. Advisors, LLC, Julian C. Baker, Felix J. Baker, FBB2, LLC, FBB Associates ×2 pengajuan 15 Juni 2012 · Pengajuan awal · SEC
Julian C. Baker, Felix J. Baker ×12 pengajuan 1 Okt. 2009 · Pengajuan awal · SEC
Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan 25 Feb. 2004 · Pengajuan awal · SEC
Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan 29 Sep. 2003 · Pengajuan awal · SEC
Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan 15 Agu 2002 · Pengajuan awal · SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

Orang dalam perusahaan 61 orang dalam · 34 pejabat · 17 direktur

19
Orang Dalam Peran Aktivitas terakhir Saham dimiliki Beli 12m Jual 12m Bersih 12m
William Meury Chief Executive Officer 16 Juli 2026 A 183.129 0 0 $0
Suketu Upadhyay EVP & Chief Financial Officer 4 Mei 2026 A 26.343 0 0 $0
Christiana Stamoulis EVP & Chief Financial Officer 15 Juli 2025 A 125.759 0 0 $0
David W Gryska Executive Vice President, CFO 16 Juli 2018 F 10.235 0 0 $0
David C Hastings Chief Financial Officer 5 Juni 2014 M 8.500 0 0 $0
Pablo J Cagnoni President, Global Head of R&D 15 Sep. 2026 M 183.200 0 9 $-14.102.143
Lee Heeson EVP, Head of Incyte Intl 1 Okt. 2026 F 37.578 0 1 $-289.017
David H Gardner EVP, Chief Strategy Officer 22 Sep. 2026 F 15.904 0 0 $0
Ramitpal K Basi EVP, Human Resources 25 Agu 2026 F 10.993 0 0 $0
Patrick A Mayes EVP & Chief Scientific Officer 5 Agu 2026 M 61.441 0 15 $-6.562.989
Michael James Morrissey EVP, Head of Tech. Operations 23 Juli 2026 A 34.065 0 3 $-5.675.002
Richard A. Hoffman EVP & General Counsel 16 Juli 2026 A 16.861 0 0 $0
Mohamed Khairie Issa EVP, Head of U.S. Commercial 16 Juli 2026 A 71.797 0 2 $-1.309.770
Thomas Tray Principal Accounting Officer 16 Juli 2026 A 21.699 0 6 $-878.953
Steven H Stein CMO & Head of Late-Stage Dev. 16 Juli 2026 A 30.916 0 6 $-7.856.771
Matteo Trotta EVP, GM, Dermatology US 25 Maret 2026 F 14.882 0 0 $0
Sheila A. Denton EVP & General Counsel 17 Nov. 2025 M 26.569 0 3 $-113.206
Vijay K Iyengar EVP, GMAPPS 16 Juli 2025 S 40.540 0 0 $0
Barry P Flannelly EVP & General Manager US 16 Juli 2025 S 35.149 0 0 $0
Paula J Swain EVP, Human Resources 15 Juli 2025 A 106.482 0 0 $0
Jonathan Elliott Dickinson EVP, General Manager, Europe 12 Sep. 2024 S 36.390 0 0 $0
Dashyant Dhanak EVP & Chief Scientific Officer 14 Juli 2023 A 58.968 0 0 $0
Maria E Pasquale EVP & General Counsel 14 Juli 2023 A 69.724 0 0 $0
Paul Trower Principal Accounting Officer 19 Jan. 2022 A 32.268 0 0 $0
Yao Wenqing EVP, Head of Discovery Chem 2 Juli 2021 A 98.575 0 0 $0
Reid M Huber EVP, Chief Scientific Officer 16 Juli 2018 F 34.571 0 0 $0
Eric H. Siegel EVP, General Counsel 13 Sep. 2017 F 21.053 0 0 $0
Richard S Levy EVP, Chief Drug Dev Officer 6 Jan. 2016 M 16.926 0 0 $0
James M Daly EVP, Chief Commercial Officer 23 Juni 2015 M 3.521 0 0 $0
Patricia S Andrews Chief Commercial Officer 19 Jan. 2012 A · 0 0 $0
Patricia A Schreck EVP, General Counsel 10 Mei 2011 M 4.500 0 0 $0
Brian W Metcalf Chief Drug Discovery Scientist 11 April 2011 M 66.504 0 0 $0
Steven M. Friedman EVP, Biology & Preclinical Dev 18 Mei 2010 A 38.137 0 0 $0
John A Keller Chief Business Officer 8 Feb. 2008 A · 0 0 $0
Paul J Clancy Direktur 30 Sep. 2026 A 25.838 0 1 $-1.423.950
Edmund Harrigan Direktur 30 Sep. 2026 A 23.225 0 0 $0
Katherine A High Direktur 8 Juni 2026 A 14.983 0 0 $0
Jacqualyn A Fouse Direktur 8 Juni 2026 A 20.968 0 0 $0
Jean Jacques Bienaime Direktur 8 Juni 2026 A 24.424 0 0 $0
Otis W Brawley Direktur 8 Juni 2026 A 12.894 0 0 $0
Herve Hoppenot Direktur 8 Des. 2025 F 326.803 0 1 $-19.773.750
Susanne Schaffert Direktur 10 Juni 2025 A 7.389 0 0 $0
Wendy L Dixon Direktur 31 Maret 2022 A 17.768 0 0 $0
Paul A Friedman, M.D. Direktur 26 Mei 2020 A 256.813 0 0 $0
Paul A Brooke Direktur 31 Maret 2020 A 221.911 0 0 $0
Barry A Ariko Direktur 12 Maret 2015 M 45.834 0 0 $0
Richard U De Schutter Direktur 5 Maret 2015 M 92.290 0 0 $0
Roy A Whitfield Direktur 17 Des. 2013 M 666.082 0 0 $0
John F Niblack Direktur 20 Mei 2011 A · 0 0 $0
Fred B Craves Direktur 1 Juni 2005 A 196.793 0 0 $0
DAMIAL FOUNDATION INC Pemilik 10% 11 Feb. 2004 S · 0 0 $0
Bonnie J Tisch Pemilik 10% 14 Jan. 2004 S · 0 0 $0
Laurent Chardonnet · 30 Maret 2015 M 2.905 0 0 $0
Julian C. Baker · 30 Mei 2013 A 66.340 0 0 $0
Matthew Emmens · 22 Mei 2008 A · 0 0 $0
HURLEY SCOTT W · 19 Jan. 2005 A · 0 0 $0
Daniel R Tisch · 12 Agu 2004 P 1.216.661 0 0 $0
TISCH THOMAS J · 12 Agu 2004 P 1.416.661 0 0 $0
James S Tisch · 12 Agu 2004 P 1.216.661 0 0 $0
Andrew H Tisch · 12 Agu 2004 P 1.216.661 0 0 $0
Jon S Saxe · 30 Maret 2004 M 80.000 0 0 $0

Orang dalam dari pengajuan SEC Form 3/4/5; bersih = hanya P/S pasar terbuka

Kepemilikan ETF Dimiliki oleh 149 ETF

20

Bobot mencerminkan kepemilikan ekuitas langsung (N-PORT) saja; dana berbasis leverage atau derivatif mungkin memiliki eksposur swap tambahan yang tidak ditampilkan.

Dana Bobot Unit Per tanggal Sumber
IDNA · iShares Trust 3,73% 77.294 SH 11 Sep. 2026 Harian
SAWG · ETF Series Solutions 3,28% 792 NS 31 Juli 2026 N-PORT
BUL · Pacer Funds Trust 3,05% 33.574 NS 31 Juli 2026 N-PORT
PBE · Invesco Exchange-Traded Fund Trust 2,51% 90.666 SH 5 Okt. 2026 Harian
SMRI · EA Series Trust 2,07% 111.793 NS 31 Juli 2026 N-PORT
FGSI · First Trust Exchange-Traded Fund IV 1,99% 344 NS 31 Juli 2026 N-PORT
POWA · Invesco Exchange-Traded Self-Indexe… 1,90% 27.325 SH 5 Okt. 2026 Harian
UPGD · Invesco Exchange-Traded Fund Trust 1,86% 18.656 SH 5 Okt. 2026 Harian
SPGP · Invesco Exchange-Traded Fund Trust 1,82% 323.220 SH 5 Okt. 2026 Harian
IBB · iShares Trust 1,81% 1.512.762 SH 11 Sep. 2026 Harian
HTEC · EXCHANGE TRADED CONCEPTS TRUST 1,80% 10.419 NS 31 Juli 2026 N-PORT
FXH · First Trust Exchange-Traded AlphaDE… 1,78% 156.306 NS 31 Juli 2026 N-PORT
RPG · Invesco Exchange-Traded Fund Trust 1,59% 269.739 SH 5 Okt. 2026 Harian
IBBQ · Invesco Exchange-Traded Fund Trust … 1,57% 14.484 SH 5 Okt. 2026 Harian
BBP · ETFis Series Trust I 1,52% 12.506 NS 31 Juli 2026 N-PORT
CALF · Pacer Funds Trust 1,52% 465.439 NS 31 Juli 2026 N-PORT
RSPH · Invesco Exchange-Traded Fund Trust 1,51% 114.489 SH 5 Okt. 2026 Harian
GURU · Global X Funds 1,37% 7.010 NS 31 Juli 2026 N-PORT
QQQJ · Invesco Exchange-Traded Fund Trust … 1,16% 119.789 SH 5 Okt. 2026 Harian
LSVD · ADVISORS' INNER CIRCLE FUND 1,04% 56.481 NS 31 Juli 2026 N-PORT
FTC · First Trust Exchange-Traded AlphaDE… 1,03% 113.368 NS 31 Juli 2026 N-PORT
INFO · Harbor ETF Trust 0,81% 57.450 NS 31 Juli 2026 N-PORT
SPVM · Invesco Exchange-Traded Fund Trust 0,80% 9.194 SH 5 Okt. 2026 Harian
LSEQ · Harbor ETF Trust 0,77% 992 NS 31 Juli 2026 N-PORT
LABU · Direxion Shares ETF Trust 0,77% 32.018 NS 31 Juli 2026 N-PORT
JOET · Virtus ETF Trust II 0,73% 14.779 NS 31 Juli 2026 N-PORT
COWG · Pacer Funds Trust 0,72% 132.772 NS 31 Juli 2026 N-PORT
BRNY · EA Series Trust 0,57% 27.866 NS 31 Juli 2026 N-PORT
PDP · Invesco Exchange-Traded Fund Trust 0,54% 70.641 SH 5 Okt. 2026 Harian
ESMV · iShares Trust 0,54% 339 SH 11 Sep. 2026 Harian
VBK · VANGUARD INDEX FUNDS 0,53% 2.249.253 SH 19 Agu 2026 Harian
FAD · First Trust Exchange-Traded AlphaDE… 0,51% 24.639 NS 31 Juli 2026 N-PORT
COWZ · Pacer Funds Trust 0,50% 774.539 NS 31 Juli 2026 N-PORT
ROUS · Lattice Strategies Trust 0,49% 29.166 NS 31 Juli 2026 N-PORT
HQGO · Lattice Strategies Trust 0,49% 2.011 NS 31 Juli 2026 N-PORT
TECB · iShares Trust 0,49% 19.516 SH 11 Sep. 2026 Harian
VLLU · Harbor ETF Trust 0,49% 189 NS 31 Juli 2026 N-PORT
USMV · iShares Trust 0,47% 910.173 SH 11 Sep. 2026 Harian
VFQY · VANGUARD WELLINGTON FUND 0,46% 19.147 SH 19 Agu 2026 Harian
ESLV · Strategy Shares 0,45% 537 NS 31 Juli 2026 N-PORT
SDG · iShares Trust 0,42% 5.697 SH 11 Sep. 2026 Harian
ACWV · iShares, Inc. 0,41% 111.137 SH 11 Sep. 2026 Harian
JPME · J.P. Morgan Exchange-Traded Fund Tr… 0,39% 15.107 NS 31 Juli 2026 N-PORT
FEX · First Trust Exchange-Traded AlphaDE… 0,38% 49.720 NS 31 Juli 2026 N-PORT
FSMD · FIDELITY COVINGTON TRUST 0,35% 72.339 NS 31 Juli 2026 N-PORT
IYH · iShares Trust 0,33% 97.043 SH 11 Sep. 2026 Harian
JPUS · J.P. Morgan Exchange-Traded Fund Tr… 0,32% 12.427 NS 31 Juli 2026 N-PORT
FHLC · FIDELITY COVINGTON TRUST 0,29% 80.584 NS 31 Juli 2026 N-PORT
VHT · VANGUARD WORLD FUND 0,28% 508.499 SH 19 Agu 2026 Harian
VFMF · VANGUARD WELLINGTON FUND 0,27% 16.793 SH 19 Agu 2026 Harian
IXJ · iShares Trust 0,26% 88.044 SH 11 Sep. 2026 Harian
SIZE · iShares Trust 0,25% 8.715 SH 11 Sep. 2026 Harian
FBUF · Fidelity Greenwood Street Trust 0,25% 498 NS 31 Juli 2026 N-PORT
VMAX · Lattice Strategies Trust 0,24% 997 NS 31 Juli 2026 N-PORT
LGDX · Tidal Trust III 0,23% 2.756 NS 31 Juli 2026 N-PORT
VB · VANGUARD INDEX FUNDS 0,23% 3.894.602 SH 19 Agu 2026 Harian
CURE · Direxion Shares ETF Trust 0,23% 3.302 NS 31 Juli 2026 N-PORT
PWS · Pacer Funds Trust 0,22% 437 NS 31 Juli 2026 N-PORT
IWS · iShares Trust 0,20% 247.446 SH 11 Sep. 2026 Harian
EUSA · iShares, Inc. 0,20% 30.370 SH 11 Sep. 2026 Harian
FTLS · First Trust Exchange-Traded Fund III 0,19% 38.962 NS 31 Juli 2026 N-PORT
RSP · Invesco Exchange-Traded Fund Trust 0,19% 1.544.793 SH 5 Okt. 2026 Harian
FHEQ · Fidelity Greenwood Street Trust 0,18% 13.826 NS 31 Juli 2026 N-PORT
IMCV · iShares Trust 0,17% 16.093 SH 11 Sep. 2026 Harian
VFMO · VANGUARD WELLINGTON FUND 0,17% 30.550 SH 19 Agu 2026 Harian
ESUM · Strategy Shares 0,16% 2.509 NS 31 Juli 2026 N-PORT
DFLV · Dimensional ETF Trust 0,16% 91.827 NS 31 Juli 2026 N-PORT
SPHQ · Invesco Exchange-Traded Fund Trust 0,16% 263.544 SH 5 Okt. 2026 Harian
VFVA · VANGUARD WELLINGTON FUND 0,16% 12.315 SH 19 Agu 2026 Harian
ESLG · Strategy Shares 0,16% 307 NS 31 Juli 2026 N-PORT
JQUA · J.P. Morgan Exchange-Traded Fund Tr… 0,16% 106.670 NS 31 Juli 2026 N-PORT
IWR · iShares Trust 0,15% 678.309 SH 11 Sep. 2026 Harian
IMCB · iShares Trust 0,14% 19.540 SH 11 Sep. 2026 Harian
EVUS · iShares Trust 0,12% 3.715 SH 11 Sep. 2026 Harian
XOEF · iShares Trust 0,12% 213 SH 11 Sep. 2026 Harian
IMCG · iShares Trust 0,12% 37.577 SH 11 Sep. 2026 Harian
DFUV · Dimensional ETF Trust 0,11% 146.271 NS 31 Juli 2026 N-PORT
DFSU · Dimensional ETF Trust 0,10% 19.945 NS 31 Juli 2026 N-PORT
OMFL · Invesco Exchange-Traded Self-Indexe… 0,10% 41.885 SH 5 Okt. 2026 Harian
ESGU · iShares Trust 0,10% 141.033 SH 11 Sep. 2026 Harian
CATH · Global X Funds 0,10% 10.371 NS 31 Juli 2026 N-PORT
DXUV · Dimensional ETF Trust 0,09% 4.162 NS 31 Juli 2026 N-PORT
SPMO · Invesco Exchange-Traded Fund Trust … 0,09% 180.304 SH 5 Okt. 2026 Harian
EQAL · Invesco Exchange-Traded Fund Trust … 0,09% 6.132 SH 5 Okt. 2026 Harian
USXF · iShares Trust 0,08% 10.050 SH 11 Sep. 2026 Harian
PALC · Pacer Funds Trust 0,08% 1.398 NS 31 Juli 2026 N-PORT
DCOR · Dimensional ETF Trust 0,08% 21.901 NS 31 Juli 2026 N-PORT
DFAC · Dimensional ETF Trust 0,07% 298.392 NS 31 Juli 2026 N-PORT
GARP · iShares Trust 0,07% 17.562 SH 11 Sep. 2026 Harian
SUSL · iShares Trust 0,06% 6.008 SH 11 Sep. 2026 Harian
CHRI · Global X Funds 0,06% 41 NS 31 Juli 2026 N-PORT
DSI · iShares Trust 0,06% 25.952 SH 11 Sep. 2026 Harian
IVW · iShares Trust 0,06% 354.438 SH 11 Sep. 2026 Harian
IUSG · iShares Trust 0,06% 147.395 SH 11 Sep. 2026 Harian
IWD · iShares Trust 0,05% 367.740 SH 11 Sep. 2026 Harian
GLOF · iShares Trust 0,05% 840 SH 11 Sep. 2026 Harian
VOOG · VANGUARD ADMIRAL FUNDS 0,05% 124.582 SH 19 Agu 2026 Harian
VONV · VANGUARD SCOTTSDALE FUNDS 0,05% 100.000 SH 19 Agu 2026 Harian
REVS · Columbia ETF Trust I 0,05% 1.396 NS 31 Juli 2026 N-PORT
EGLE · Global X Funds 0,05% 9 NS 31 Juli 2026 N-PORT
HAPI · Harbor ETF Trust 0,05% 1.975 NS 31 Juli 2026 N-PORT
PRF · Invesco Exchange-Traded Fund Trust 0,05% 38.897 SH 5 Okt. 2026 Harian
DFVX · Dimensional ETF Trust 0,05% 1.993 NS 31 Juli 2026 N-PORT
IUS · Invesco Exchange-Traded Self-Indexe… 0,04% 3.572 SH 5 Okt. 2026 Harian
DFAU · Dimensional ETF Trust 0,04% 43.168 NS 31 Juli 2026 N-PORT
TOV · EA Series Trust 0,04% 910 NS 31 Juli 2026 N-PORT
TOPC · iShares Trust 0,04% 100 SH 11 Sep. 2026 Harian
ILCV · iShares Trust 0,04% 3.819 SH 11 Sep. 2026 Harian
XVV · iShares Trust 0,04% 1.907 SH 11 Sep. 2026 Harian
XYLG · Global X Funds 0,03% 186 NS 31 Juli 2026 N-PORT
XCLR · Global X Funds 0,03% 10 NS 31 Juli 2026 N-PORT
XRMI · Global X Funds 0,03% 133 NS 31 Juli 2026 N-PORT
IVV · iShares Trust 0,03% 2.115.770 SH 11 Sep. 2026 Harian
XYLD · Global X Funds 0,03% 8.564 NS 31 Juli 2026 N-PORT
PTLC · Pacer Funds Trust 0,03% 8.472 NS 31 Juli 2026 N-PORT
ILCB · iShares Trust 0,03% 3.242 SH 11 Sep. 2026 Harian
BBUS · J.P. Morgan Exchange-Traded Fund Tr… 0,03% 22.989 NS 31 Juli 2026 N-PORT
VOTE · TCW ETF Trust 0,03% 2.822 NS 31 Juli 2026 N-PORT
QVML · Invesco Exchange-Traded Fund Trust … 0,03% 4.476 SH 5 Okt. 2026 Harian
BKLC · BNY Mellon ETF Trust 0,03% 13.892 NS 31 Juli 2026 N-PORT
VOO · VANGUARD INDEX FUNDS 0,03% 4.357.457 SH 19 Agu 2026 Harian
VTI · VANGUARD INDEX FUNDS 0,03% 5.391.866 SH 19 Agu 2026 Harian
VONE · VANGUARD SCOTTSDALE FUNDS 0,03% 27.427 SH 19 Agu 2026 Harian
VTHR · VANGUARD SCOTTSDALE FUNDS 0,03% 13.959 SH 19 Agu 2026 Harian
PBP · Invesco Exchange-Traded Fund Trust 0,03% 1.013 SH 5 Okt. 2026 Harian
ESGV · VANGUARD WORLD FUND 0,03% 37.474 SH 19 Agu 2026 Harian
DFUS · Dimensional ETF Trust 0,03% 51.979 NS 31 Juli 2026 N-PORT
XTR · Global X Funds 0,03% 12 NS 31 Juli 2026 N-PORT
PBUS · Invesco Exchange-Traded Fund Trust … 0,03% 27.329 SH 5 Okt. 2026 Harian
IWB · iShares Trust 0,03% 114.458 SH 11 Sep. 2026 Harian
IYY · iShares Trust 0,03% 7.092 SH 11 Sep. 2026 Harian
SPUU · Direxion Shares ETF Trust 0,03% 634 NS 31 Juli 2026 N-PORT
QDPL · Pacer Funds Trust 0,03% 4.037 NS 31 Juli 2026 N-PORT
DYNF · BlackRock ETF Trust 0,03% 95.298 SH 11 Sep. 2026 Harian
IWV · iShares Trust 0,03% 45.601 SH 11 Sep. 2026 Harian
ITOT · iShares Trust 0,03% 215.857 SH 11 Sep. 2026 Harian
RWL · Invesco Exchange-Traded Fund Trust … 0,03% 23.053 SH 5 Okt. 2026 Harian
ACVF · ETF Opportunities Trust 0,03% 345 NS 31 Juli 2026 N-PORT
RECS · Columbia ETF Trust I 0,03% 13.186 NS 31 Juli 2026 N-PORT
ILCG · iShares Trust 0,03% 6.647 SH 11 Sep. 2026 Harian
TOK · iShares Trust 0,03% 485 SH 11 Sep. 2026 Harian
TILT · FlexShares Trust 0,03% 4.582 NS 31 Juli 2026 N-PORT
HCMT · Direxion Shares ETF Trust 0,02% 1.167 NS 31 Juli 2026 N-PORT
PHDG · Invesco Actively Managed Exchange-T… 0,02% 133 SH 5 Okt. 2026 Harian
SPXL · Direxion Shares ETF Trust 0,02% 13.118 NS 31 Juli 2026 N-PORT
URTH · iShares, Inc. 0,02% 14.482 SH 11 Sep. 2026 Harian
ACWI · iShares Trust 0,02% 55.495 SH 11 Sep. 2026 Harian
VT · VANGUARD INTERNATIONAL EQUITY INDEX… 0,02% 142.324 SH 19 Agu 2026 Harian
CRBN · iShares Trust 0,01% 876 SH 11 Sep. 2026 Harian

INCY Konsensus Analis Opini analis bullish dan bearish, target harga 12 bulan, potensi kenaikan

21
peringkat · 35 analis BELI
Target median $129.00 +14,4%
8 22,9% Beli Kuat
10 28,6% Beli
17 48,6% Tahan
0 0,0% Jual
0 0,0% Jual Kuat

Target Harga 12 Bulan

24 analis · 2026-10-06

Target rata-rata $128.92 +14,4%

Sekarang Harga saat ini $112.73
Rendah$86.00 Rata-rata$128.92 Tinggi$157.00

Perbandingan rekan (sub-industri GICS) Metrik utama vs rekan sektor

22

Dasar FY, harga per penutupan akhir tahun fiskal terakhir setiap perusahaan.

Ticker Kapitalisasi Pasar P/E Pendapatan YoY Margin Bersih ROE Margin Kotor
INCY $19.60B 15.4 21.2% 25.0% 27.6% ·
RVMD · · · · · ·
BIIB $25.84B 20.0 2.2% 13.1% 7.2% ·
ALNY $52.64B 170.7 65.2% 8.5% 60.4% ·
UTHR $21.27B 17.5 10.6% 41.9% 18.7% 87.9%
INSM $37.29B -27.1 66.7% -210.5% -128.4% ·
NBIX $14.20B 30.4 21.4% 16.7% 16.1% ·
EXEL $11.44B 15.7 7.0% 33.7% 37.3% ·
SMMT $13.56B -12.1 · · -235.1% ·
BBIO $14.90B -20.2 126.3% -146.0% 41.2% ·
HALO $7.93B 26.3 37.5% 22.7% 166.1% ·

Berita Terbaru Berita utama terbaru yang menyebutkan perusahaan ini

23
Incyte Sales Growth Drives Share Price Gains Yahoo Finance · 1 bulan, 3 minggu lalu Adagene (ADAG) Bermitra Dengan Incyte (INCY) untuk Mengevaluasi Terapi Kombinasi untuk Kanker Kolorektal Yahoo Finance · 5 bulan, 2 minggu lalu

Sinyal Perdagangan Sinyal beli/jual terbaru dengan harga masuk dan rasio risiko/imbalan

25
BLUECHIP_DIP Stop out Jun 1
risiko 1 imbalan 5,00
masuk $95.85 R:R 5,00
BLUECHIP_DIP Kedaluwarsa Apr 9
risiko 1 imbalan 5,00
masuk $95.27 R:R 5,00
BLUECHIP_DIP Kedaluwarsa Mar 23
risiko 1 imbalan 1,30
masuk $91.77 R:R 1,30

Tidak ada sinyal terbuka saat ini — tidak ada kartu yang terisi, dan itu jujur.

Metrik Saya Daftar pantauan pribadi Anda — baris yang dipilih dari Fundamental Lengkap

26

Pilih metrik yang penting bagi Anda — klik + di sebelah baris mana pun di Fundamental Lengkap di atas.

Pilihan Anda disimpan dan mengikuti Anda di semua ticker.

Sumber: SEC 10-Q diajukan Jul 28, 2026